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It was only 3 years ago that an acquired translocation of EML4withALK leading to the expression of an EML4-
ALK oncoprotein in non-small cell lung cancer (NSCLC) was reported. Tumor cells expressing EML4-ALK are
‘‘addicted’’ to its continued function. Now, crizotinib, an oral ALK inhibitor, is demonstrated to provide
dramatic clinical benefit with little toxicity in patients having such advanced NSCLC, and a mechanism of
clinical resistance to crizotinib is identified. Such therapy ‘‘targeted’’ at oncogenic proteins provides
‘‘personalized’’ medicine and prompts genome-wide mutation analysis of human tumors to find other
therapeutic targets.An Amazing, Rapid Success Story of Translational
Cancer Research
In 2007, rearrangements of the anaplastic lymphoma kinase
(ALK) gene in non-small cell lung cancer (NSCLC) were reported
(Soda et al., 2007). Less than 3 years later, studies of ALK inhibi-
tion yielding dramatic response rates in patients with advanced
NSCLC containing ALK-rearrangements and determination of
the mechanism of resistance to the ALK-targeted therapy were
reported in the New England Journal of Medicine (Choi et al.,
2010; Kwak et al., 2010). Together, these reports represent
a stunning and rapid translation of preclinical molecular findings
into the clinic. In a pretreated patient population that generally
has a 10% response rate to conventional chemotherapy, treat-
ment with the oral ALK inhibitor crizotinib yielded an overall
response rate of 55% and an estimated 6 month, progression-
free survival rate of 72%. In addition, the mechanism of
resistance was associated with mutations in the ALK kinase
domain, providing genetic evidence that ALK was indeed the
target of the ‘‘targeted’’ therapy. During this brief period, transla-
tional research provided insights into ALK biology, clinicopatho-
logic features of the target population, development of a clinical
diagnostic test, drug development, and identification of resis-
tance mechanisms. By contrast, analogous development for
other druggable kinases, such as breakpoint cluster region-
Abelson (BCR-ABL) in chronic myeloid leukemia and epidermal
growth factor receptor (EGFR) mutations in NSCLC, unfolded
over decades (see Table 1). This rapid clinical development of
ALK-targeted therapy was greatly accelerated, in part by
previous experience with clinical development of other tyrosine
kinase inhibitors (TKIs) and in part by the fact that crizotinib
(PF-02341066, Pfizer), which was developed initially as a MET
inhibitor but was soon realized to also be an ALK inhibitor, was
developed before the EML4-ALK translocation was identified
in NSCLC (Christensen et al., 2007; Zou et al., 2007).
EML4-ALK is the latest of tumor-associated genetic changes
providing a very specific therapeutic target along with a genetic
diagnostic test to ‘‘personalize’’ this therapy. Such success has548 Cancer Cell 18, December 14, 2010 ª2010 Elsevier Inc.led to a number of international consortium approaches for
genome-wide tumor sequencing in lung and other cancers to
identify all of the somatically acquired genetic (and epigenetic)
changes in an individual tumor that could represent new
diagnostic and therapeutic targets (Ciccarelli, 2010; Ding et al.,
2008; Forbes et al., 2010; Kan et al., 2010; Lee et al., 2010;
Pleasance et al., 2010; Syed et al., 2010; Thomas et al., 2007;
Weir et al., 2007). It has also led to academic consortia, such
as the Cancer Target Discovery and Development Network
(CTD2N) of the National Cancer Institute (NCI), to integrate
genomics and new chemical compound screening for develop-
ment of patient-based therapeutics (Schreiber et al., 2010).
From this information, we hope to identify additional therapeutic
targets as well as a method for ‘‘personalizing’’ their application
for lung and other cancer patients (Janku et al., 2010).
Integration of Discoveries of Genetic Abnormalities,
Preclinical and Early Clinical Studies
ALK encodes a tyrosine kinase normally expressed only in
certain neuronal cells. The ALK gene was originally identified
through cloning of the t(2;5)(p23;q35) translocation found in
a subset of anaplastic large cell lymphomas (Morris et al.,
1994). In a rare subset of NSCLCs, interstitial deletion and
inversion within chromosome 2p result in fusion of the N-terminal
portion of the protein encoded by the echinoderm microtubule-
associated protein-like 4 (EML4) gene with the intracellular
signaling portion of the ALK receptor tyrosine kinase (Soda
et al., 2007). While genetic alterations involving ALK have been
identified in other malignancies, thus far, the EML4-ALK fusion
gene appears unique to NSCLC. A number of EML4-ALK vari-
ants have been identified in NSCLCs, all of which appear to
confer gain-of-function properties (Choi et al., 2008). Equivalent
to EGFRmutations,EML4-ALK fusions result in constitutive tyro-
sine kinase activity, dependence of the cancer cell on activated
downstream mitogenic pathways, and exquisite sensitivity to
ALK inhibition, and thus represents another case of ‘‘oncogene
addiction’’ (Weinstein and Joe, 2008).






























Median PFS 11 mos
Median OS 31 mos
RR 30%
Median PFS 5 mos
Median OS 24 mos
2004
KIT 1998 GIST 6,000 Imatinib RR 55%
Median PFS 27 mos
Median OS 58 mos
RR 5%
Median OS 20 mos
2002
BRAF 2002 V600E BRAF
mutated melanoma
(50% of melanoma)
34,000 PLX4032 RR 77%
Median PFS 7 mos





ALK 2007 EML4-ALK NSCLC
(5% of NSCLC)
8,500 Crizotinib RR 55%
6 month PFS 70%
OS not yet determined
RR 25%
Median PFS 4-6 mos
Median OS 12 mos
2010
ALK, anaplastic lymphoma kinase; CML, chronic myeloid leukemia; EGFR, epidermal growth factor receptor; GIST, gastrointestinal stromal tumor;
NSCLC, non-small cell lung cancer; OS, overall survival; PFS, progression-free survival; RR, response rate; mos, months.
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population, and early phase clinical development proceeded
together rapidly. In transgenic mice expressing EML4-ALK in
lung epithelial cells, numerous bilateral lung adenocarcinomas
develop shortly after birth, supporting the oncogenic nature of
this fusion protein (Soda et al., 2008). Administration of a specific
inhibitor of ALK tyrosine kinase activity resulted in rapid eradica-
tion of these nodules. In 2008, a phase I clinical trial was initiated,
followed in 2009 by reports of caseswith dramatic clinical benefit
of ALK-targeted therapy among patients with ALK-positive
NSCLC (Kwak et al., 2009), which in 2010, led to the opening
of a phase 3 registration trial of crizotinib in ALK-positive
patients.
Clinicopathologic Features of EML4-ALK NSCLCs
Central to this remarkable progress has been an early under-
standing of the clinicopathologic features of EML4-ALK NSCLC,
which represents 5% of all NSCLCs (Kwak et al., 2010; Rodig
et al., 2009; Shaw et al., 2009). In general, patients with NSCLCs
harboringALK rearrangements tend to be younger and have little
(<10 pack-years) to no smoking history. Almost all cases have
been adenocarcinomas, predominantly signet-ring cell type
with abundant intracellular mucin. While this histologic pattern
is well recognized in gastrointestinal and breast adenocarci-
nomas, it is rarely observed in lung cancer. EML4-ALK
rearrangements appear to be mutually exclusive of EGFR and
KRAS mutations, and, by contrast to EGFR mutant NSCLCs,
there does not appear to be an association with patient ethnicity,
gender, or differential outcomes with combination platinum-
based chemotherapy.
Clinical Diagnostic Test
Absolutely essential for the clinical application of ALK-targeted
therapy is a tumor clinical diagnostic to identify patients most
likely to respond. Evidence of EML4-ALK in lung tumors hasbeen documented by fluorescence in situ hybridization (FISH),
immunohistochemistry (IHC), and reverse transcriptase
polymerase chain reaction (RT-PCR). Of these, FISH appears
to be the most clinically applicable. EML4-ALK FISH employs
differently labeled break-apart (split-signal) probes on the 50
and 30 ends of the ALK gene. ALK rearrangements appear as
separate red and green signals, while normal ALK generates
a fused (yellow) signal. Using a cut-off of >15% of cells and
examining 4+ fields (approximately 60 cells), virtually 100%
sensitivity and specificity have been reported (Camidge et al.,
2010). ALK IHC is fraught with technical and interpretive
challenges, but tyramide amplification appears to improve its
yield from 40% to 80%.(Rodig et al., 2009) While RT-PCR is
potentially the most sensitive assay, it requires adequate RNA
quantity and quality, which are difficult to obtain in routine clinical
samples, aswell asmultiple PCRprimers to detect the numerous
known fusion transcripts.
Important Role of Multi-Institutional
and Multidisciplinary Collaborative Efforts
Given the rarity of ALK rearrangements in NSCLC, clinical
advancement has required multi-institutional, international, and
multi-disciplinary collaboration. To identify 82 ALK-positive
patients, Kwak and colleagues screened 1,500 patients over
18 months (Kwak et al., 2010). Patients were treated with
crizotinib, a dual inhibitor of ALK and MET tyrosine kinases,
250 mg orally twice daily. All patients tested negative for MET
amplification, suggesting that therapeutic effect was achieved
via ALK inhibition. Because of neuronal localization of ALK
expression, the patients were closely monitored. However,
crizotinib waswell tolerated, withmild nausea and diarrhea, tran-
sient visual disturbances without ophthalmologic findings, and
rare elevations in liver chemistries. Radiographic response was
assessed every 8 weeks, and crizotinib treatment was associ-
ated with many months of disease control in nearly 75% ofCancer Cell 18, December 14, 2010 ª2010 Elsevier Inc. 549
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quantitative clinical benefit with mild to no toxicities.
Ascertainment of Resistance to ALK-Targeted Therapy
Was of Great Importance
Identification of the precise mechanism(s) by which tumors
become resistant to targeted therapy has yielded important
information and thus needs to be studied in initial clinical trials,
acknowledging that such study requires rebiopsying of patient’s
tumors at the time of relapse. Thus, it was of great interest that
accompanying the report of the crizotinib clinical trial, molecular
analysis of an EML4-ALK fusion NSCLC that had relapsed on
crizotinib therapy was reported by another group (Choi et al.,
2010). The resistant tumor had acquired two mutations in the
tumor ALK tyrosine kinase domain (C1156Y and L1196M) that
appear to be in two subpopulations of tumor cells. In vitro, cells
engineered to express either of thesemutant ALK fusion proteins
were resistant to crizotinib and other ALK inhibitors compared to
ALK fusion protein without these changes. The authors pre-
sented pictures of the predicted ALK structure, locating the
mutations with reference to the crizotinib binding site, and noted
that amino acid L1196M corresponds to the imatinib resistance
BCR-ABL T315I mutation found in chronic myelogenous leuke-
mias, and gefitinib and erlotinib resistance EGFR T790M
mutation found in NSCLCs. These findings strongly suggest
L1196M is a ‘‘gatekeeper’’ mutation, which confers resistance
to tyrosine kinase inhibitors via altered ATP binding and steric
hindrance of drug binding. The mechanism of resistance of
C1156, an activating mutation on the N-terminal side of ALK, is
less clear.
A lesson learned from resistance to EGFR TKI-targeted
therapy in EGFR mutant NSCLCs was that resistance could
come from either an EGFR mutation or amplification of MET
(providing a bypass of the blocked pathway), and, thus, there
will likely be other mechanisms of crizotinib resistance discov-
ered. In addition, EGFR TKI-resistant clones are often present
as minor subpopulations in the original tumor (Ercan et al.,
2010; Turke et al., 2010). With knowledge of resistance
mutations and new sensitive assays it may be possible to not
only type tumors for the first targeted therapy, but also identify,
before such therapy, resistant subpopulations that will arise.
Thus, the development of targeted therapy mutations in the
very protein being targeted provides genetic evidence that ALK
was indeed the key target, sets the stage for developing the
next generation of drugs to overcome such resistance, and
provides powerful molecular probes to monitor emergence of
drug resistant populations.
ALK-Targeted Therapy Benefited from Previous Studies
of Targeted Agents
The rapid development of ALK inhibition owesmuch to the expe-
rience gained from use of EGFR inhibitors for treating NSCLC.
Only after thousands of patients were treated with EGFR TKIs
gefitinib or erlotinib were activating EGFR mutations—and thus
a target population—identified. In fact, many clinical trials in
patients whose tumors were not typed for EGFR mutations
demonstrated negative and possibly detrimental effects, espe-
cially in patients receiving concurrent EGFR TKIs with carbopla-
tin-paclitaxel chemotherapy or concurrent chemo-radiation550 Cancer Cell 18, December 14, 2010 ª2010 Elsevier Inc.therapy (Herbst et al., 2005; Kelly et al., 2008). When EGFR
TKIs were applied to NSCLCs containing EGFR mutations,
clinical benefits became obvious (Janku et al., 2010). These find-
ings led to the design of clinical trials for ALK-targeted therapy.
‘‘Tissue Is the Issue’’
Until about 10 years ago, nearly every newly diagnosed patient
with lung cancer had an adequate biopsy to allow for clear histo-
logic diagnosis of lung cancer. In efforts to make things ‘‘easier’’
on patients and as a cost-saving measure, invasive diagnostic
biopsies have been forsaken for fine needle aspirates and
a cytologic diagnosis. Thus, in routine clinical practice, lung
cancer diagnoses are made on examination of only a few cells.
Clearly, if targeted therapies are going to be used we will need
to screen patients’ tumors for a large number of mutations for
targeting therapy, potentially performing total genomic analyses.
This will mean a return to dedicated surgical biopsies and correct
handling of tissues (e.g., frozen tissues) to facilitate such
analyses. While studies of circulating tumor cells or other easy
to obtain biomarkers in blood and body fluids may provide
such information, for the next several years it would seem
prudent to return to better tumor tissue sampling methods, given
that the information has the potential to personalize each
patient’s treatment and in certain cases provide dramatic clinical
benefit. Currently, the NCI’s multi-institutional Lung Cancer
Mutation Consortium (LCMC) is performing mutational analysis
of a large panel of genes including EML4-ALK on tumor samples
from 1,000 patients with advanced lung adenocarcinoma, and
this prospective study will provide a wealth of information on
the frequency of such ‘‘actionable’’ mutations.
Targeted Therapy Will Make Clinical Trials Both Easier
and More Complex
Clearly, the ability to treat a patient population selected for the
EML4-ALK fusion protein mutation greatly facilitated the clinical
development of ALK-targeted therapy. However, we point out
future complexities that will need to be addressed. While
ALK-targeted therapy is clinically beneficial in patientswithmeta-
static NSCLC, it will also have to be tested in randomized trials in
early stage (e.g., stages I and II) resected NSCLCs; given the
mutation frequency, this will be difficult. One reason for this
caution is a recent analysis suggesting a detrimental effect on
overall survival when patients with early-stage NSCLC harboring
EGFR mutations received adjuvant (postoperative) gefitinib.
Potent and well-tolerated targeted cancer therapies such as
ALK inhibitors are also forcing clinical researchers to face new
questions about the design and conduct of clinical trials. For
example, in a phase 3 trial of patients with advanced BRAF
mutated melanoma designed to fulfill FDA guidelines for drug
approval, patientswere randomized to PLX4032, awell-tolerated
BRAF inhibitor associated with response rates exceeding 75%,
and the ‘‘standard therapy’’ with dacarbazine, an alkylating agent
with considerable toxicity and, historically, little efficacy. Patients
assigned to dacarbazine were not permitted to cross over to
experimental therapy, generating an ethical debate recently
featured in the New York Times (http://www.nytimes.com/2010/
09/19/health/research/19trial.html?ref=target_cancer). Because
of such dilemmas, ongoing phase 3 trials of crizotinib for ALK-
positive NSCLC permitted cross-over to the experimental arm
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targeted therapy.
An Uncommon Mutation in a Common Disease
Is Numerically Important
Although EML4-ALK is observed in only a small fraction of lung
cancers, because lung cancer is such a prevalent disease, there
are likely up to 10,000 cases per year of ALK-positive NSCLCs in
the United States—more than the total number of cases of
several other malignancies (Jemal et al., 2010). Of note, tumor-
acquired ALK fusion proteins are found in lymphomas, neuro-
blastomas, and other malignancies (Kelleher and McDermott,
2010). In fact, a patient with inflammatory fibrous tumor
harboring RANBP2-ALK fusion responding to crizotinib was
reported in the same issue of the New England Journal of Medi-
cine (Butrynski et al., 2010). Ongoing efforts to perform genome
wide sequencing on large numbers of malignancies will likely
increase the total numbers of tumors that will benefit from
ALK-targeted therapy.
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